Whitehawk Therapeutics (WHWK) Gross Margin (2021 - 2025)

Whitehawk Therapeutics (WHWK) has 5 years of Gross Margin data on file, last reported at 89.36% in Q1 2025.

• Gross Margin for Q1 2025 came in at 89.36%, up 154.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 89.36% (up 100.0% YoY), and the FY2025 annual result was 89.36%, up 100.0% from the prior year.
• Gross Margin was little changed at 89.36% in Q1 2025 per WHWK's latest filing, from 89.09% in the prior quarter.
• Over five years, Gross Margin peaked at 100.0% in Q4 2021 and troughed at 85.35% in Q4 2023.
• A 5-year average of 90.05% and a median of 89.23% in 2024 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2023 and 2024: Gross Margin sank 1041 bps in 2023, then soared 374 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 100.0% in 2021, then retreated by 4 bps to 95.75% in 2022, then declined by 11 bps to 85.35% in 2023, then increased by 4 bps to 89.09% in 2024, then advanced by 0 bps to 89.36% in 2025.
• Business Quant data shows WHWK's Gross Margin at 89.36% in Q1 2025, 89.09% in Q4 2024, and 88.85% in Q3 2024.